Urokinase is a proteolytic enzyme extracted from the culture medium of
human urine or kidney thin face tissue, which can directly activate fibrinogen
to become fibrinolytic enzyme, thus hydrolyzing fibrin and dissolving thrombi.
After intravenous injection of this drug, the activity of fibrinolytic enzyme
increased rapidly, reaching the peak in 15 minutes, still increasing 6 hours
later, and returning to normal slowly 24 hours later.
Urokinase USES the same as streptokinase, but has a weaker effect. At
present, it is mainly used for intravenous thrombolytic therapy in acute
myocardial infarction or coronary artery, and can also be used for other
thromboembolic diseases, eye inflammation, traumatic tissue edema, hematoma,
etc. In addition, there are anti-lung cancer metastasis effect, pregnancy
poisoning, systemic lupus erythematosus also has a certain effect. Adverse
reactions include bleeding, fever, anaphylaxis, etc., but the drug has no
antigenicity, no pyrogenicity, and severe anaphylaxis is rare. Excessive dosage
can cause bleeding, aminohexanoic acid and other anti-fibrinolytic drugs can be
used to fight treatment.